Literature DB >> 18375953

Characterization of the conformational alterations, reduced anticoagulant activity, and enhanced antiangiogenic activity of prelatent antithrombin.

Benjamin Richard1, Richard Swanson, Sophia Schedin-Weiss, Ben Ramirez, Gonzalo Izaguirre, Peter G W Gettins, Steven T Olson.   

Abstract

A conformationally altered prelatent form of antithrombin that possesses both anticoagulant and antiangiogenic activities is produced during the conversion of native to latent antithrombin (Larsson, H., Akerud, P., Nordling, K., Raub-Segall, E., Claesson-Welsh, L., and Björk, I. (2001) J. Biol. Chem. 276, 11996-12002). Here, we show that the previously characterized prelatent antithrombin is a mixture of native antithrombin and a modified, true prelatent antithrombin that are resolvable by heparin-agarose chromatography. Kinetic analyses revealed that prelatent antithrombin is an intermediate in the conversion of native to latent antithrombin whose formation is favored by stabilizing anions of the Hofmeister series. Purified prelatent antithrombin had reduced anticoagulant function compared with native antithrombin, due to a reduced heparin affinity and consequent impaired ability of heparin to either bridge prelatent antithrombin and coagulation proteases in a ternary complex or to induce full conformational activation of the serpin. Significantly, prelatent antithrombin possessed an antiangiogenic activity more potent than that of latent antithrombin, based on the relative abilities of the two forms to inhibit endothelial cell growth. The prelatent form was conformationally altered from native antithrombin as judged from an attenuation of tryptophan fluorescence changes following heparin activation and a reduced thermal stability. The alterations are consistent with the limited structural changes involving strand 1C observed in a prelatent form of plasminogen activator inhibitor-1 (Dupont, D. M., Blouse, G. E., Hansen, M., Mathiasen, L., Kjelgaard, S., Jensen, J. K., Christensen, A., Gils, A., Declerck, P. J., Andreasen, P. A., and Wind, T. (2006) J. Biol. Chem. 281, 36071-36081), since the (1)H NMR spectrum, electrophoretic mobility, and proteolytic susceptibility of prelatent antithrombin most resemble those of native rather than those of latent antithrombin. Together, these results demonstrate that limited conformational alterations of antithrombin that modestly reduce anticoagulant activity are sufficient to generate antiangiogenic activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18375953      PMCID: PMC2386924          DOI: 10.1074/jbc.M710327200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity.

Authors:  H Larsson; P Akerud; K Nordling; E Raub-Segall; L Claesson-Welsh; I Björk
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

2.  Structure of a serpin-protease complex shows inhibition by deformation.

Authors:  J A Huntington; R J Read; R W Carrell
Journal:  Nature       Date:  2000-10-19       Impact factor: 49.962

3.  Maspin is an angiogenesis inhibitor.

Authors:  M Zhang; O Volpert; Y H Shi; N Bouck
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

Review 4.  Identification of critical molecular interactions mediating heparin activation of antithrombin: implications for the design of improved heparin anticoagulants.

Authors:  Steven T Olson; Ingemar Björk; Susan C Bock
Journal:  Trends Cardiovasc Med       Date:  2002-07       Impact factor: 6.677

5.  Kallistatin is a new inhibitor of angiogenesis and tumor growth.

Authors:  Robert Q Miao; Jun Agata; Lee Chao; Julie Chao
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

6.  Formation of the antithrombin heterodimer in vivo and the onset of thrombosis.

Authors:  A Zhou; J A Huntington; R W Carrell
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

7.  Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells.

Authors:  H Larsson; T Sjöblom; J Dixelius; A Ostman; K Ylinenjärvi; I Björk; L Claesson-Welsh
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

8.  Generation of multiple angiogenesis inhibitors by human pancreatic cancer.

Authors:  O Kisker; S Onizuka; J Banyard; T Komiyama; C M Becker; E G Achilles; C M Barnes; M S O'Reilly; J Folkman; S R Pirie-Shepherd
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

9.  The size and shape of human and bovine antithrombin III.

Authors:  B Nordenman; C Nyström; I Björk
Journal:  Eur J Biochem       Date:  1977-08-15

10.  Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin.

Authors:  U Lindahl; G Bäckström; L Thunberg; I G Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

View more
  5 in total

1.  Three case reports of inherited antithrombin deficiency in China: double novel missense mutations, a nonsense mutation and a frameshift mutation.

Authors:  Haoyu Deng; Wei Shen; Yi Gu; Xiong Ma; Jiwei Zhang; Lan Zhang
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

2.  Saturation Mutagenesis of the Antithrombin Reactive Center Loop P14 Residue Supports a Three-step Mechanism of Heparin Allosteric Activation Involving Intermediate and Fully Activated States.

Authors:  Ryan Roth; Richard Swanson; Gonzalo Izaguirre; Susan C Bock; Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2015-09-10       Impact factor: 5.157

3.  Interaction of antithrombin with sulfated, low molecular weight lignins: opportunities for potent, selective modulation of antithrombin function.

Authors:  Brian L Henry; Justin Connell; Aiye Liang; Chandravel Krishnasamy; Umesh R Desai
Journal:  J Biol Chem       Date:  2009-06-04       Impact factor: 5.157

4.  Antiangiogenic forms of antithrombin specifically bind to the anticoagulant heparin sequence.

Authors:  Sophia Schedin-Weiss; Benjamin Richard; Rebecka Hjelm; Steven T Olson
Journal:  Biochemistry       Date:  2008-12-23       Impact factor: 3.162

5.  Anti-Tumor Functions of Prelatent Antithrombin on Glioblastoma Multiforme Cells.

Authors:  Julia Peñas-Martínez; Ginés Luengo-Gil; Salvador Espín; Nataliya Bohdan; Carmen Ortega-Sabater; Maria Carmen Ródenas; David Zaragoza-Huesca; María José López-Andreo; Carme Plasencia; Vicente Vicente; Alberto Carmona-Bayonas; Irene Martínez-Martínez
Journal:  Biomedicines       Date:  2021-05-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.